Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21567908 | 0.83 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL3254719 | 0.80 | ACHE (0.52) | IDO1ACP3DPP4 | |
| SCHEMBL3259002 | 0.80 | ACHE (0.52) | IDO1ACP3DPP4 | |
| SCHEMBL12569050 | 0.80 | ACHE (0.52) | IDO1ACP3DPP4 | |
| SCHEMBL17519154 | 0.76 | ADRB2 (0.45) | IDO1KMT2AACP3DPP4NPC1 | |
| SCHEMBL19619720 | 0.73 | SLC6A4 (0.44) | KMT2AACP3DPP4HTT | |
| SCHEMBL11080962 | 0.73 | ENPP2 (0.45) | PTGS2ENPP2 | |
| SCHEMBL17519158 | 0.72 | CASR (0.41) | IDO1KMT2AACP3DPP4RAB9A | |
| SCHEMBL5811040 | 0.72 | PTGS2 (0.50) | PTGS2ENPP2 | |
| SCHEMBL2162305 | 0.71 | GAA (0.57) | KMT2ADPP4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345141-A1 | ARYL-SUBSTITUTED IMIDAZOLES | ST JUDE CHILDRENS RES HOSPITAL (US) | 2019-11-14 | — | — | US | disclosed |
| EP-2621275-B1 | ARYL-SUBSTITUTED IMIDAZOLES | ST JUDE CHILDRENS RES HOSPITAL (US) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345141-A1 | ARYL-SUBSTITUTED IMIDAZOLES | MDM2, TP53, MDM4 | IDO1 46/4885PTGS2 4132/4885PTGS1 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.